Soligenix Virus Candidate More Critical Than Ever with Marburg Virus Outbreak in Africa

Authorities in Equatorial Guinea are working to contain an outbreak of Marburg virus that began in February 2023 and has resulted in 11 deaths and 48 additional documented cases of the disease. Marburg virus can have a fatality rate of up to 88% and has no approved vaccine or cure.

Late-stage biopharmaceutical company, Soligenix, Inc., (Nasdaq: SNGX) is advancing the only heat stable subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and Marburg viruses.

As the U.S. government continues to ramp up efforts to prevent future outbreaks and pandemics, Soligenix’s cost-effective, thermostable vaccine candidate has the potential to be a lifesaver.

The Soligenix Solution

  • Soligenix’s Marburg virus vaccine candidate has demonstrated 100% protection in non-human primates against both Marburg marburgvirus and Sudan ebolavirus.
  • The candidate is a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with sterile water immediately prior to use.
  • Vaccines prepared using Soligenix’s proprietary ThermoVax® platform have been shown to maintain full potency and thermostability at temperatures as high as 104 degrees Fahrenheit for as long as 12 months.
  • ThermoVax® has the potential to eliminate the need for cold chain distribution and storage of vaccines in regions where the distribution network or power supply may be uncertain.

What’s Next?

  • Additional preclinical animal data for the ThermoVax® platform technology is anticipated in the second quarter.
  • The development of Soligenix’s vaccines is part of an ongoing long-term collaboration with the company’s academic partner, the University of Hawaiʽi at Mānoa. The program has been supported by a number of innovation and government grants.
  • In October 2022, Soligenix was invited by the Biomedical Advanced Research and Development Authority (BARDA) to submit a full contract proposal for a potential multi-year, multi-million dollar contract to develop SuVax™ and MarVax™ vaccine candidates as medical countermeasures against a Sudan ebolavirus or Marburg marburgvirus

 Find Out More

 Soligenix’s Chief Scientific Officer, Dr. Oreola Donini, provides more information about Soligenix’s Thermostabilized Filovirus Vaccine Platform in this video interview.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Soligenix Virus Candidate More Critical Than Ever with Marburg Virus Outbreak in Africa

Editor Prism MarketView